D
Iovance Biotherapeutics, Inc.
IOVA
$3.30
$0.247.84%
D
Sell
11/20/2024Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 11/20/2024 due to an increase in the growth index, total return index and valuation index. Total revenue increased 88.24% from $31.11M to $58.56M, operating cash flow increased 40.09% from -$98.43M to -$58.97M, and earnings per share increased from -$0.3409 to -$0.2755.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 11/20/2024 due to an increase in the growth index, total return index and valuation index. Total revenue increased 88.24% from $31.11M to $58.56M, operating cash flow increased 40.09% from -$98.43M to -$58.97M, and earnings per share increased from -$0.3409 to -$0.2755.
E
Sell
10/24/2024Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 10/24/2024 due to a decline in the volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 10/24/2024 due to a decline in the volatility index.
D
Sell
5/17/2024Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 5/17/2024 due to a large increase in the solvency index, growth index and total return index. The quick ratio increased from 2.54 to 4.28, total revenue increased 48.34% from $482 to $715, and earnings per share increased from -$0.4561 to -$0.4244.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 5/17/2024 due to a large increase in the solvency index, growth index and total return index. The quick ratio increased from 2.54 to 4.28, total revenue increased 48.34% from $482 to $715, and earnings per share increased from -$0.4561 to -$0.4244.
E
Sell
3/1/2024Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 3/1/2024 due to a decline in the solvency index, growth index and valuation index. The quick ratio declined from 3.97 to 2.54, and EBIT declined 2.45% from -$118.36M to -$121.26M.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 3/1/2024 due to a decline in the solvency index, growth index and valuation index. The quick ratio declined from 3.97 to 2.54, and EBIT declined 2.45% from -$118.36M to -$121.26M.
D
Sell
2/22/2024Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 2/22/2024 due to an increase in the volatility index and total return index.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 2/22/2024 due to an increase in the volatility index and total return index.
E
Sell
2/7/2024Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 2/7/2024 due to a decline in the volatility index and growth index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 2/7/2024 due to a decline in the volatility index and growth index.
D
Sell
1/23/2024Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 1/23/2024 due to an increase in the total return index and volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 1/23/2024 due to an increase in the total return index and volatility index.
E
Sell
1/5/2024Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 1/5/2024 due to a decline in the volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 1/5/2024 due to a decline in the volatility index.
D
Sell
12/18/2023Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 12/18/2023 due to an increase in the growth index, solvency index and volatility index. Total revenue increased 97.06% from $238 to $469, the quick ratio increased from 2.83 to 3.97, and operating cash flow increased 10.5% from -$93.95M to -$84.08M.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 12/18/2023 due to an increase in the growth index, solvency index and volatility index. Total revenue increased 97.06% from $238 to $469, the quick ratio increased from 2.83 to 3.97, and operating cash flow increased 10.5% from -$93.95M to -$84.08M.
E
Sell
10/3/2023Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 10/3/2023 due to a decline in the volatility index and total return index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 10/3/2023 due to a decline in the volatility index and total return index.
D
Sell
9/15/2023Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 9/15/2023 due to an increase in the volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 9/15/2023 due to an increase in the volatility index.
E
Sell
8/28/2023Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 8/28/2023 due to a decline in the volatility index and total return index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 8/28/2023 due to a decline in the volatility index and total return index.
D
Sell
8/10/2023Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 8/10/2023 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 5.87% from -$99.82M to -$93.95M, earnings per share increased from -$0.5024 to -$0.4746, and EBIT increased 0.69% from -$110.86M to -$110.09M.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 8/10/2023 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 5.87% from -$99.82M to -$93.95M, earnings per share increased from -$0.5024 to -$0.4746, and EBIT increased 0.69% from -$110.86M to -$110.09M.
E
Sell
7/31/2023Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 7/31/2023 due to a decline in the volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 7/31/2023 due to a decline in the volatility index.
D
Sell
7/13/2023Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 7/13/2023 due to an increase in the growth index, solvency index and volatility index. The quick ratio increased from 5.16 to 7.18, debt to equity declined from 0.03 to 0.02, and earnings per share increased from -$0.6392 to -$0.5024.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 7/13/2023 due to an increase in the growth index, solvency index and volatility index. The quick ratio increased from 5.16 to 7.18, debt to equity declined from 0.03 to 0.02, and earnings per share increased from -$0.6392 to -$0.5024.
E
Sell
3/16/2023Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 3/16/2023 due to a decline in the volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 3/16/2023 due to a decline in the volatility index.
D
Sell
3/1/2023Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 3/1/2023 due to an increase in the solvency index, volatility index and total return index. The quick ratio increased from 4.55 to 5.16.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 3/1/2023 due to an increase in the solvency index, volatility index and total return index. The quick ratio increased from 4.55 to 5.16.
E
Sell
2/15/2023Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 2/15/2023 due to a decline in the volatility index and valuation index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 2/15/2023 due to a decline in the volatility index and valuation index.
D
Sell
1/26/2023Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 1/26/2023 due to an increase in the volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 1/26/2023 due to an increase in the volatility index.
E
Sell
1/10/2023Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 1/10/2023 due to a decline in the volatility index and total return index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 1/10/2023 due to a decline in the volatility index and total return index.
D
Sell
12/12/2022Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 12/12/2022 due to an increase in the volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 12/12/2022 due to an increase in the volatility index.
E
Sell
11/25/2022Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 11/25/2022 due to a decline in the volatility index and total return index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 11/25/2022 due to a decline in the volatility index and total return index.
D
Sell
11/4/2022Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 11/4/2022 due to an increase in the growth index and volatility index. Operating cash flow increased 18.02% from -$77.64M to -$63.65M, and earnings per share increased from -$0.6317 to -$0.6312.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 11/4/2022 due to an increase in the growth index and volatility index. Operating cash flow increased 18.02% from -$77.64M to -$63.65M, and earnings per share increased from -$0.6317 to -$0.6312.
E
Sell
10/20/2022Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 10/20/2022 due to a decline in the volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 10/20/2022 due to a decline in the volatility index.
D
Sell
9/30/2022Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 9/30/2022 due to an increase in the valuation index and total return index.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 9/30/2022 due to an increase in the valuation index and total return index.
E
Sell
8/8/2022Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 8/8/2022 due to a noticeable decline in the total return index, growth index and solvency index. EBIT declined 8.75% from -$91.71M to -$99.73M, earnings per share declined from -$0.5831 to -$0.6317, and operating cash flow declined 5.19% from -$73.8M to -$77.64M.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 8/8/2022 due to a noticeable decline in the total return index, growth index and solvency index. EBIT declined 8.75% from -$91.71M to -$99.73M, earnings per share declined from -$0.5831 to -$0.6317, and operating cash flow declined 5.19% from -$73.8M to -$77.64M.
D
Sell
6/6/2022Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to D- from D on 6/6/2022 due to a decline in the total return index and volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to D- from D on 6/6/2022 due to a decline in the total return index and volatility index.
D
Sell
5/16/2022Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D from E+ on 5/16/2022 due to an increase in the valuation index.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D from E+ on 5/16/2022 due to an increase in the valuation index.
E
Sell
5/13/2022Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D on 05/13/2022.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D on 05/13/2022.
D
Sell
5/12/2022Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D from D- on 5/12/2022 due to an increase in the growth index. Earnings per share increased from -$0.633 to -$0.5831, and EBIT increased 7.79% from -$99.47M to -$91.71M.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D from D- on 5/12/2022 due to an increase in the growth index. Earnings per share increased from -$0.633 to -$0.5831, and EBIT increased 7.79% from -$99.47M to -$91.71M.
D
Sell
5/5/2022Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index and total return index.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index and total return index.
E
Sell
4/20/2022Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 4/20/2022 due to a decline in the valuation index, total return index and volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to E+ from D- on 4/20/2022 due to a decline in the valuation index, total return index and volatility index.
D
Sell
3/31/2022Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to D- from D on 3/31/2022 due to a noticeable decline in the total return index, volatility index and solvency index. The quick ratio declined from 8.9 to 5.65.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to D- from D on 3/31/2022 due to a noticeable decline in the total return index, volatility index and solvency index. The quick ratio declined from 8.9 to 5.65.
D
Sell
11/23/2021Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index and volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index and volatility index.
D
Sell
11/8/2021Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to D- from D on 11/8/2021 due to a significant decline in the total return index, volatility index and growth index. Operating cash flow declined 6.82% from -$54.01M to -$57.69M, EBIT declined 5.91% from -$81.43M to -$86.24M, and earnings per share declined from -$0.5291 to -$0.5538.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to D- from D on 11/8/2021 due to a significant decline in the total return index, volatility index and growth index. Operating cash flow declined 6.82% from -$54.01M to -$57.69M, EBIT declined 5.91% from -$81.43M to -$86.24M, and earnings per share declined from -$0.5291 to -$0.5538.
D
Sell
5/1/2020Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index.
D
Sell
2/28/2020Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to D- from D on 2/28/2020 due to a noticeable decline in the growth index, solvency index and efficiency index. Net income declined 28.45% from -$49.49M to -$63.57M, operating cash flow declined 27.59% from -$42.18M to -$53.82M, and earnings per share declined from -$0.399 to -$0.5034.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to D- from D on 2/28/2020 due to a noticeable decline in the growth index, solvency index and efficiency index. Net income declined 28.45% from -$49.49M to -$63.57M, operating cash flow declined 27.59% from -$42.18M to -$53.82M, and earnings per share declined from -$0.399 to -$0.5034.
D
Sell
5/11/2018Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D from D- on 5/11/2018 due to an increase in the growth index, efficiency index and solvency index. Total capital increased 101.1% from $145.48M to $292.56M, the quick ratio increased from 14.7 to 20.22, and operating cash flow increased 14.86% from -$20.96M to -$17.85M.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D from D- on 5/11/2018 due to an increase in the growth index, efficiency index and solvency index. Total capital increased 101.1% from $145.48M to $292.56M, the quick ratio increased from 14.7 to 20.22, and operating cash flow increased 14.86% from -$20.96M to -$17.85M.
D
Sell
3/13/2018Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to D- from D on 3/13/2018 due to a decline in the valuation index and efficiency index. Net income declined 16.73% from -$22.15M to -$25.85M, and total capital declined 12.06% from $165.44M to $145.48M.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to D- from D on 3/13/2018 due to a decline in the valuation index and efficiency index. Net income declined 16.73% from -$22.15M to -$25.85M, and total capital declined 12.06% from $165.44M to $145.48M.
D
Sell
11/2/2017Upgraded
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D from D- on 11/2/2017 due to an increase in the total return index and volatility index.
Iovance Biotherapeutics, Inc. (IOVA) was upgraded to D from D- on 11/2/2017 due to an increase in the total return index and volatility index.
D
Sell
8/11/2017Downgrade
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to D- from D on 8/11/2017 due to a decline in the total return index, solvency index and efficiency index. The quick ratio declined from 26.75 to 14.56, total capital declined 13.83% from $149.89M to $129.15M, and net income declined 13.02% from -$20.68M to -$23.38M.
Iovance Biotherapeutics, Inc. (IOVA) was downgraded to D- from D on 8/11/2017 due to a decline in the total return index, solvency index and efficiency index. The quick ratio declined from 26.75 to 14.56, total capital declined 13.83% from $149.89M to $129.15M, and net income declined 13.02% from -$20.68M to -$23.38M.
D
Sell
2/8/2017Upgraded
Lion Biotechnologies, Inc. (LBIO) was upgraded to D from D- on 2/8/2017 due to an increase in the total return index.
Lion Biotechnologies, Inc. (LBIO) was upgraded to D from D- on 2/8/2017 due to an increase in the total return index.
D
Sell
1/17/2017Downgrade
Lion Biotechnologies, Inc. (LBIO) was downgraded to D- from D on 1/17/2017 due to a decline in the volatility index, growth index and solvency index. Earnings per share declined from -$0.2264 to -$1.1539, operating cash flow declined 225.75% from -$3.75M to -$12.21M, and EBIT declined 61.84% from -$11.73M to -$18.98M.
Lion Biotechnologies, Inc. (LBIO) was downgraded to D- from D on 1/17/2017 due to a decline in the volatility index, growth index and solvency index. Earnings per share declined from -$0.2264 to -$1.1539, operating cash flow declined 225.75% from -$3.75M to -$12.21M, and EBIT declined 61.84% from -$11.73M to -$18.98M.
D
Sell
5/2/2016Upgraded
Lion Biotechnologies, Inc. (LBIO) was upgraded to D from D- on 5/2/2016 due to an increase in the total return index and volatility index.
Lion Biotechnologies, Inc. (LBIO) was upgraded to D from D- on 5/2/2016 due to an increase in the total return index and volatility index.
D
Sell
3/11/2016Downgrade
Lion Biotechnologies, Inc. (LBIO) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the total return index, volatility index and growth index. Operating cash flow declined 71.18% from -$3.84M to -$6.58M, earnings per share declined from -$0.1615 to -$0.1886, and EBIT declined 10.61% from -$7.64M to -$8.45M.
Lion Biotechnologies, Inc. (LBIO) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the total return index, volatility index and growth index. Operating cash flow declined 71.18% from -$3.84M to -$6.58M, earnings per share declined from -$0.1615 to -$0.1886, and EBIT declined 10.61% from -$7.64M to -$8.45M.
D
Sell
7/21/2015Downgrade
Lion Biotechnologies, Inc. (LBIO) was downgraded to D from D+ on 7/21/2015 due to a substantial decline in the volatility index and total return index.
Lion Biotechnologies, Inc. (LBIO) was downgraded to D from D+ on 7/21/2015 due to a substantial decline in the volatility index and total return index.
D
Sell
6/25/2015Upgraded
Lion Biotechnologies, Inc. (LBIO) was upgraded to D+ from D on 6/25/2015 due to an increase in the valuation index and volatility index.
Lion Biotechnologies, Inc. (LBIO) was upgraded to D+ from D on 6/25/2015 due to an increase in the valuation index and volatility index.
D
Sell
6/10/2015Downgrade
Lion Biotechnologies, Inc. (LBIO) was downgraded to D from D+ on 6/10/2015 due to a decline in the total return index, volatility index and valuation index.
Lion Biotechnologies, Inc. (LBIO) was downgraded to D from D+ on 6/10/2015 due to a decline in the total return index, volatility index and valuation index.
D
Sell
5/20/2015Upgraded
Lion Biotechnologies, Inc. (LBIO) was upgraded to D+ from D on 5/20/2015 due to a major increase in the total return index, growth index and solvency index. The quick ratio increased from 27.03 to 58.24, EBIT increased 8.83% from -$4.87M to -$5.3M, and operating cash flow increased 4.33% from -$3.31M to -$3.46M.
Lion Biotechnologies, Inc. (LBIO) was upgraded to D+ from D on 5/20/2015 due to a major increase in the total return index, growth index and solvency index. The quick ratio increased from 27.03 to 58.24, EBIT increased 8.83% from -$4.87M to -$5.3M, and operating cash flow increased 4.33% from -$3.31M to -$3.46M.
D
Sell
3/28/2014Downgrade
Genesis Biopharma, Inc. (LBIO) was downgraded to D from C on 3/28/2014 due to a significant decline in the valuation index, efficiency index and growth index. Total capital declined 626.98% from -$3.34M to $17.6M.
Genesis Biopharma, Inc. (LBIO) was downgraded to D from C on 3/28/2014 due to a significant decline in the valuation index, efficiency index and growth index. Total capital declined 626.98% from -$3.34M to $17.6M.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
